Tìm theo
Astemizole
Các tên gọi khác (7 ) :
  • 1-(P-Fluorobenzyl)-2-((1-(2-(P-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
  • 1-(P-Fluorobenzyl)-2-((1-(P-methoxyphenethyl)-4-piperidyl)amino)benzimidazole
  • Astemison
  • Astemizol
  • Astemizol
  • Astémizole
  • Astemizolum
Thuốc chống dị ứng & dùng trong các trường hợp quá mẫn
Thuốc Gốc
Small Molecule
CAS: 68844-77-9
ATC: R06AX11
CTHH: C28H31FN4O
PTK: 458.5703
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
458.5703
Monoisotopic mass
458.248189839
InChI
InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)
InChI Key
InChIKey=GXDALQBWZGODGZ-UHFFFAOYSA-N
IUPAC Name
1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine
Traditional IUPAC Name
astemizole
SMILES
COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
Độ tan chảy
149.1 °C
Độ hòa tan
432 mg/L
logP
5.8
logS
-5.6
pKa (Strongest Basic)
8.75
PSA
42.32 Å2
Refractivity
135.64 m3·mol-1
Polarizability
52.08 Å3
Rotatable Bond Count
8
H Bond Acceptor Count
4
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
5
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Astemizole is a second generation H1-receptor antagonist. It does not significantly cross the blood brain barrier and therefore does not cause drowsiness or CNS depression at normal doses.
Cơ Chế Tác Dụng : Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. Astemizole competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of astemizole to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier and preferentially binds at H1 receptors in the peripehery rather than within the brain, CNS depression is minimal. Astemizole may also act on H3-receptors, producing adverse effects.
Dược Động Học :
▧ Absorption :
Rapidly absorbed from the gastrointestinal tract.
▧ Protein binding :
96.7%
▧ Metabolism :
Almost completely metabolized in the liver and primarily excreted in the feces.
▧ Half Life :
1 day
Độc Tính : LD50=2052mg/kg in mice
Chỉ Định : Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
Tương Tác Thuốc :
  • Amprenavir Increased risk of cardiotoxicity and arrhythmias
  • Aprepitant Increased risk of cardiotoxicity and arrhythmias
  • Bepridil Increased risk of cardiotoxicity and arrhythmias
  • Cimetidine Increased risk of cardiotoxicity and arrhythmias
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Clarithromycin Increased risk of cardiotoxicity and arrhythmias
  • Delavirdine Increased risk of cardiotoxicity and arrhythmias
  • Efavirenz Increased risk of cardiotoxicity and arrhythmias
  • Erythromycin Increased risk of cardiotoxicity and arrhythmias
  • Fluoxetine Increased risk of cardiotoxicity and arrhythmias
  • Fluvoxamine Increased risk of cardiotoxicity and arrhythmias
  • Fosamprenavir Increased risk of cardiotoxicity and arrhythmias
  • Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
  • Indinavir Increased risk of cardiotoxicity and arrhythmias
  • Itraconazole Increased risk of cardiotoxicity and arrhythmias
  • Josamycin Increased risk of cardiotoxicity and arrhythmias
  • Ketoconazole Increased risk of cardiotoxicity and arrhythmias
  • Mesoridazine Increased risk of cardiotoxicity and arrhythmias
  • Mibefradil Increased risk of cardiotoxicity and arrhythmias
  • Nefazodone Increased risk of cardiotoxicity and arrhythmias
  • Nelfinavir Increased risk of cardiotoxicity and arrhythmias
  • Posaconazole Contraindicated co-administration
  • Quinine Increased risk of cardiotoxicity and arrhythmias
  • Quinupristin This combination presents an increased risk of toxicity
  • Ritonavir Increased risk of cardiotoxicity and arrhythmias
  • Saquinavir Increased risk of cardiotoxicity and arrhythmias
  • Sparfloxacin Increased risk of cardiotoxicity and arrhythmias
  • Telavancin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Telithromycin Increased risk of cardiotoxicity and arrhythmias
  • Thioridazine Increased risk of cardiotoxicity and arrhythmias
  • Tipranavir Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated.
  • Troleandomycin Increased risk of cardiotoxicity and arrhythmias
  • Voriconazole Increased risk of cardiotoxicity and arrhythmias
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty : Lupin
    Sản phẩm biệt dược : Acemiz
  • Công ty : Incobra
    Sản phẩm biệt dược : Alerkin
  • Công ty : Senosiain
    Sản phẩm biệt dược : Astesen
  • Công ty : Janssen
    Sản phẩm biệt dược : Hismanal
  • Công ty : Biofarma
    Sản phẩm biệt dược : Histalong
  • Công ty : Bruluart
    Sản phẩm biệt dược : Lergibrumizol
  • Công ty : Cadila HC
    Sản phẩm biệt dược : Stemiz
... loading
... loading